Literature DB >> 16436499

Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.

Mary J Clark1, Cheryse A Furman, Timra D Gilson, John R Traynor.   

Abstract

Pertussis toxin (PTX)-insensitive mutants of Galpha(i/o) proteins expressed in C6mu cells were used to examine the hypothesis that there are agonist-specific conformational states of the mu-opioid receptor with coupling preferences to different Galpha(i/o) subtypes, as measured by the degree of stimulation of [(35)S]guanosine 5'-O-(3-thio)triphosphate (GTPgammaS) binding. Binding of [(35)S]GTPgammaS to endogenous Galpha(i/o) proteins stimulated by the full mu-opioid agonist [d-Ala(2),MePhe(4),Gly(5)-ol]enkephalin (DAMGO) was completely blocked by overnight treatment with 100 ng/ml PTX. Treatment for 4 h with lower concentrations led to a PTX-dependent reduction in the maximal effect of DAMGO but no alteration in the potency of DAMGO or morphine nor in the relative maximal effect (relative efficacy) of the partial agonists morphine and buprenorphine compared with the full agonist DAMGO. Using PTX-insensitive Galpha mutants in which the PTX-sensitive cysteine was replaced with isoleucine, the potency for a series of mu-opioid agonists was highest in cells expressing Galpha(i3) and Galpha(o) and lowest with Galpha(i1) and Galpha(i2), with no significant change in the order of potency, namely, etorphine >> endomorphin-1 = DAMGO = endomorphin-2 = fentanyl = morphine >> meperidine. The order of agonist relative efficacy, etorphine = DAMGO = endomorphin-1 = endomorphin-2 = fentanyl > or = morphine > or = meperidine > buprenorphine > or = nalbuphine, was also the same across all of the PTX-insensitive Galpha(i/o) subtypes. Highest relative efficacy to stimulate [(35)S]GTPgammaS binding was seen with Galpha(i3). Consequently, reported observations of agonist-directed trafficking at mu-opioid receptors most likely involve non-PTX-sensitive Galpha protein mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436499     DOI: 10.1124/jpet.105.096818

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

Review 1.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.

Authors:  Jamie McPherson; Guadalupe Rivero; Myma Baptist; Javier Llorente; Suleiman Al-Sabah; Cornelius Krasel; William L Dewey; Chris P Bailey; Elizabeth M Rosethorne; Steven J Charlton; Graeme Henderson; Eamonn Kelly
Journal:  Mol Pharmacol       Date:  2010-07-20       Impact factor: 4.436

Review 3.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

4.  Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.

Authors:  Neil T Burford; Mary J Clark; Tom S Wehrman; Samuel W Gerritz; Martyn Banks; Jonathan O'Connell; John R Traynor; Andrew Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

5.  Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Authors:  Devki D Sukhtankar; Nurulain T Zaveri; Stephen M Husbands; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2013-05-07       Impact factor: 4.030

6.  Synaptic mechanism for functional synergism between delta- and mu-opioid receptors.

Authors:  Zhi Zhang; Zhizhong Z Pan
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

7.  μ-Opioid receptor coupling to Gα(o) plays an important role in opioid antinociception.

Authors:  Jennifer T Lamberts; Emily M Jutkiewicz; Richard M Mortensen; John R Traynor
Journal:  Neuropsychopharmacology       Date:  2011-06-08       Impact factor: 7.853

8.  Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent.

Authors:  Jeffery N Talbot; David L Roman; Mary J Clark; Rebecca A Roof; John J G Tesmer; Richard R Neubig; John R Traynor
Journal:  J Neurochem       Date:  2009-11-30       Impact factor: 5.372

Review 9.  Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: from pharmacological curiosity to therapeutic potential.

Authors:  Susan L Ingram; John R Traynor
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

10.  Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.

Authors:  Colette M Cremeans; Erin Gruley; Donald J Kyle; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.